OR WAIT null SECS
September 07, 2022
Lynparza has been approved in Great Britain as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Sanofi’s Xenpozyme (olipudase alfa-rpcp) is now the only approved treatment for acid sphingomyelinase deficiency.
Touchlight will expand Lonza’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material.
The patent applications are for programs concerning lupus, idiopathic pulmonary fibrosis, and chronic kidney disease.
September 02, 2022
Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio.
August 30, 2022
Thermo Fisher Scientific’s new 300,000 ft² facility, located in Plainville, Mass., will specialize in manufacturing viral vectors.
Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.
Novavax’s COVID-19 vaccine, Nuvaxovid, can now be given to adolescents aged 12 to 17 in the UK.
August 29, 2022
Moderna is suing Pfizer and BioNTech for allegedly infringing on patents the company filed from 2010 to 2016.
August 24, 2022
Aerie to be purchased by Alcon after recently bringing two glaucoma drugs to market.